Literature DB >> 3731076

Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy.

J S Cohen, R C Lyon, C Chen, P J Faustino, G Batist, M Shoemaker, E Rubalcaba, K H Cowan.   

Abstract

31P magnetic resonance spectra of perfused human breast cancer cells with the phenotype of pleiotropic drug resistance exhibit striking differences in the levels of phosphate metabolites from the wild-type, drug-sensitive parent cell line. Resistant cells demonstrated elevated levels of phosphocreatine and depressed levels of phosphomonoesters, phosphodiesters, and diphosphodiesters. These differences may reflect significant alterations in the control of bioenergetic metabolism between drug-resistant and -sensitive cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3731076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  MRI and MRS of intact perfused cancer cell metabolism, invasion, and stromal cell interactions.

Authors:  Marie-France Penet; Tariq Shah; Flonne Wildes; Balaji Krishnamachary; Santosh K Bharti; Jesus Pacheco-Torres; Dmitri Artemov; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2019-01-28       Impact factor: 4.044

2.  Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays.

Authors:  N W Lutz; S E Franks; M H Frank; S Pomer; W E Hull
Journal:  MAGMA       Date:  2005-06-23       Impact factor: 2.310

3.  Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

Authors:  Joseph A Ludwig; Gergely Szakács; Scott E Martin; Benjamin F Chu; Carol Cardarelli; Zuben E Sauna; Natasha J Caplen; Henry M Fales; Suresh V Ambudkar; John N Weinstein; Michael M Gottesman
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

4.  Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells.

Authors:  Wei Jin; Kathleen W Scotto; William N Hait; Jin-Ming Yang
Journal:  Biochem Pharmacol       Date:  2007-06-17       Impact factor: 5.858

Review 5.  Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies.

Authors:  O Kaplan; J S Cohen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Fructose-2,6-bisphosphate synthesis by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) is required for the glycolytic response to hypoxia and tumor growth.

Authors:  Jason Chesney; Jennifer Clark; Alden C Klarer; Yoannis Imbert-Fernandez; Andrew N Lane; Sucheta Telang
Journal:  Oncotarget       Date:  2014-08-30

7.  NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell line.

Authors:  S de Jong; N H Mulder; E G de Vries; G T Robillard
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

8.  Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy.

Authors:  C J Twelves; D A Porter; M Lowry; N A Dobbs; P E Graves; M A Smith; R D Rubens; M A Richards
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

9.  31P nuclear magnetic resonance spectroscopy, histology and cytokinetics of a xenografted hypopharynx carcinoma following treatment with cisplatin: comparison in three sublines with increasing resistance.

Authors:  R Tausch-Treml; P Köpf-Maier; F Baumgart; B Gewiese; D Ziessow; H Scherer; K J Wolf
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

10.  The assessment of treatment response in non-Hodgkin's lymphoma by image guided 31P magnetic resonance spectroscopy.

Authors:  S R Smith; P A Martin; J M Davies; R H Edwards; A N Stevens
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.